2020
DOI: 10.1038/s41409-020-01165-x
|View full text |Cite
|
Sign up to set email alerts
|

Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
10
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 10 publications
(10 citation statements)
references
References 34 publications
0
10
0
Order By: Relevance
“…This negative impact on relapse-free survival (RFS) is explained by exon 17 mutations (including D816V ) alone, and the role of the exon 8/10/11 mutation remains elusive. Similar concerns apply to the case of a double CEBPA mutation, which is not considered a favorable prognostic factor in the presence of chromatin, cohesion, or splicing factor mutations 6 . In addition, this opinion should be updated because it has recently been shown that CEBPA with in-frame mutations in the bZip domain, rather than double mutations, confers a favorable impact on outcomes.…”
Section: Allo-sct For Aml In Cr1 In the Era Of Genomicsmentioning
confidence: 98%
See 2 more Smart Citations
“…This negative impact on relapse-free survival (RFS) is explained by exon 17 mutations (including D816V ) alone, and the role of the exon 8/10/11 mutation remains elusive. Similar concerns apply to the case of a double CEBPA mutation, which is not considered a favorable prognostic factor in the presence of chromatin, cohesion, or splicing factor mutations 6 . In addition, this opinion should be updated because it has recently been shown that CEBPA with in-frame mutations in the bZip domain, rather than double mutations, confers a favorable impact on outcomes.…”
Section: Allo-sct For Aml In Cr1 In the Era Of Genomicsmentioning
confidence: 98%
“…Ahn et al . explored the role of MRD in AML CR1 patients with normal karyotype ( n =124), which would significantly overlap with the ELN intermediate prognosis group 6 . They showed that allo-SCT recipients had significantly longer overall survival (OS) compared with those who received chemotherapy alone in the MRD pos group, while the outcome was almost the same for the MRD neg group, irrespective of allo-SCT.…”
Section: Allo-sct For Aml In Cr1 In the Era Of Genomicsmentioning
confidence: 99%
See 1 more Smart Citation
“…The survival analysis was performed following the protocol outlined in a previous study [33]. Consequently, Mantel-Byar tests were used to compare the survival data, the Simon and Makuch method was used for graphical representation, and time-dependent multivariate Cox proportional hazard models were used to examine time-dependent covariates by considering allogeneic HCT as a time-dependent covariate [34].…”
Section: Statistical Analysesmentioning
confidence: 99%
“…In recent years, NGS assay has been used in monitoring minimal (measurable) residual disease (MRD). Using unique molecular identification (UMI) barcode, NGS sequencing error and noise background have been reduced, which makes NGS assay a good tool in monitoring MRD [9][10][11][12][13][14][15][16] . NGS assay has also been used in single cell sequencing, which is a powerful tool for revealing information about clonal evolution 17,18 .…”
Section: Ngsmentioning
confidence: 99%